Which stocks are affected by the growth of AUVELITY and SUNOSI?

**Bottom-line 🏁:** Axsome Therapeutics (NASDAQ: AXSM) is the clear “headline beneficiary” of the rapid uptake of AUVELITY and SUNOSI, but a handful of other names—Jazz Pharmaceuticals (JAZZ), 3M India, and even Sunoco (SUN) via a very indirect channel—also feel the ripple effects of this CNS/sleep-disorder powerhouse. 📈✨ --- ### 1. Axsome Therapeutics (AXSM) – the core growth engine 🚀 • AUVELITY alone drove **$136.1 million** in Q3 net product sales—**+69 % YoY**—and now enjoys **75 % commercial coverage**. • SUNOSI added **$32.8 million** (+35 % YoY) and is helping push total revenue **+63 % YoY to $171 million**. • Management expects gross-to-net discounts to edge toward the low-50 % range in Q4, yet still projects cash to fund operations “into cash-flow positivity”. • A trend-similarity model even pegs AXSM’s fair value at **$136.28** with a bullish bias and max upside of **22.66 %**. --- ### 2. Jazz Pharmaceuticals (JAZZ) – the “other” Sunosi shareholder 🤝 • Axsome **acquired U.S. rights to Sunosi in May 2022** and has since grown sales from **$42.2 million H1-2024** to **$32.8 million Q3-2025** (note: different reporting periods, but trend is positive). • Because Jazz had already booked its upfront payment, Axsome’s ramp now translates into **royalty revenue** for Jazz—creating a secondary, lower-beta growth kicker for the Irish partner. 🎉 --- ### 3. 3M India – an unexpected side-note 📊 • During its Q2 FY26 call, 3M India highlighted **broad-based growth across all four business segments**, including Healthcare (+14.9 %), Consumer (+14.6 %), and more. • While not directly tied to AUVELITY/SUNOSI, the company’s diversified growth narrative shows how **multi-divisional corporates can still outpace peers** even when single-product stories dominate headlines. 🧩 --- ### 4. Sunoco (SUN) – a stretch connection 🛢️ • Wells Fargo just **upgraded SUN to Overweight** and lifted its price target to **$65** on merger synergies and improved FCF prospects. • The link? A **high-yield energy infrastructure play** can attract capital that might otherwise chase biotech momentum—so strong Sunoco results can **pull liquidity away** from growth names like AXSM, creating a mild competitive effect for investors’ dollars. 🏦 --- ### Quick comparison table 📋 | Company | Primary link to AUVELITY/SUNOSI | Recent financial impact | Key takeaway | |---------|--------------------------------|-------------------------|--------------| | Axsome (AXSM) | Sole commercializer | Q3 revenue +63 % YoY; AUVELITY +69 %, SUNOSI +35 % | Core beneficiary; strong growth & cash runway | | Jazz (JAZZ) | Royalties on Sunosi | Sales data show Sunosi growth trend | Secondary beneficiary via royalty stream | | 3M India | None (included for context) | Segment growth +12-15 % | Diversified growth story; no direct link | | Sunoco (SUN) | None (liquidity effect) | Upgrade & PT hike | Market sentiment can shift capital flows | --- **Curious thought to ponder 🤔:** If AUVELITY’s Alzheimer’s agitation sNDA gets approved, Axsome could unlock a whole new patient population—how might that reshape the competitive landscape for CNS drugs, and which other under-the-radar names could suddenly find themselves in the spotlight? 🌟